University of Texas Southwestern Medical Center 9th Annual Update on Liver Disease 2025

Advanced Hepatology, Cirrhosis, MASH & Liver Cancer Management Update

The University of Texas Southwestern Medical Center 9th Annual Update on Liver Disease 2025 provides a comprehensive review of contemporary hepatology and liver disease management. This advanced educational program delivers practical, evidence-based updates on the diagnosis, treatment, and long-term management of metabolic dysfunction-associated steatohepatitis (MASH), alcohol-associated liver disease (ALD), autoimmune liver disorders, cirrhosis complications, and hepatocellular carcinoma (HCC).

Directed by leading hepatology experts from UT Southwestern, the course combines clinical updates, case-based discussions, and guideline-driven recommendations designed to help healthcare professionals optimize patient outcomes across the spectrum of liver disease.

Product Details

• Course Date: December 6, 2025
• Format: 21 Videos (.mp4) + 21 Audios (.mp3) + 21 Subtitle Files (.vtt) + 15 PDFs
• Size: 5.72 GB
• Access: On-Demand
• Provider: University of Texas Southwestern Medical Center

Program Overview

Liver disease continues to evolve as one of the fastest-growing areas in gastroenterology and internal medicine. New therapeutic options, evolving diagnostic criteria, advances in imaging, and emerging treatment strategies are transforming the management of chronic liver disease and its complications.

The 9th Annual Update on Liver Disease 2025 provides practical education on:

• Metabolic dysfunction-associated steatohepatitis (MASH)
• Alcohol-associated liver disease (ALD)
• Autoimmune hepatitis (AIH)
• Primary biliary cholangitis (PBC)
• Primary sclerosing cholangitis (PSC)
• Cirrhosis and portal hypertension
• Ascites management
• Spontaneous bacterial peritonitis (SBP)
• Portal vein thrombosis
• Hepatocellular carcinoma (HCC)
• Liver lesion evaluation
• Addiction medicine in hepatology
• Advanced liver imaging

The curriculum emphasizes evidence-based clinical decision-making and practical management strategies that can be immediately implemented in clinical practice.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Apply updated guidelines for the management of MASH and metabolic liver disease.
• Integrate weight-loss therapies and GLP-1 receptor agonists into hepatology care.
• Diagnose and manage autoimmune liver diseases including AIH, PSC, and PBC.
• Develop treatment strategies for complications of cirrhosis and portal hypertension.
• Incorporate addiction medicine principles into the care of patients with alcohol-associated liver disease.
• Utilize current approaches to HCC surveillance and liver lesion evaluation.
• Apply LI-RADS classification systems when interpreting liver imaging.
• Improve outcomes through multidisciplinary management of chronic liver disease.

MASH & Metabolic Liver Disease

A major focus of the conference is the rapidly evolving management of metabolic dysfunction-associated steatohepatitis (MASH).

Topics include:

• MASH diagnosis
• Metabolic dysfunction-associated steatotic liver disease (MASLD)
• Risk stratification
• Weight loss interventions
• Lifestyle modification
• GLP-1 receptor agonists
• Emerging pharmacologic therapies
• Fibrosis assessment

Faculty discuss evidence-based strategies for slowing disease progression and reducing liver-related complications.

Alcohol-Associated Liver Disease (ALD)

The course reviews modern approaches to alcohol-related liver injury and addiction-focused care.

Topics include:

• Alcohol-associated liver disease
• Alcoholic hepatitis
• Liver fibrosis progression
• Addiction medicine integration
• Behavioral interventions
• Relapse prevention
• Multidisciplinary patient management

Participants gain practical tools for addressing both liver disease and underlying substance use disorders.

Autoimmune Liver Diseases

Dedicated sessions review the diagnosis and treatment of autoimmune hepatobiliary disorders.

Topics include:

• Autoimmune hepatitis (AIH)
• Primary biliary cholangitis (PBC)
• Primary sclerosing cholangitis (PSC)
• Autoimmune liver injury
• Immunosuppressive therapy
• Disease monitoring
• Long-term management strategies

Faculty highlight advances in diagnosis and evolving treatment paradigms.

Cirrhosis & Portal Hypertension

The conference provides comprehensive updates on managing complications of advanced liver disease.

Topics include:

• Cirrhosis evaluation
• Portal hypertension
• Ascites management
• Hepatic decompensation
• Spontaneous bacterial peritonitis (SBP)
• Portal vein thrombosis
• Hospitalized cirrhosis patients
• Prognostic assessment

Participants learn practical approaches to improving outcomes in patients with advanced liver disease.

Hepatocellular Carcinoma (HCC)

Early detection and treatment of liver cancer remain essential components of hepatology practice.

Topics include:

• HCC surveillance
• Liver cancer screening
• Risk stratification
• Imaging interpretation
• Multidisciplinary treatment planning
• Early-stage HCC management
• Advanced liver cancer therapies

Faculty review current recommendations and emerging developments in hepatocellular carcinoma care.

Liver Imaging & LI-RADS

The course explores contemporary imaging approaches for evaluating focal liver lesions.

Topics include:

• Liver lesion characterization
• LI-RADS classification
• Ultrasound surveillance
• CT and MRI interpretation
• Diagnostic algorithms
• Benign versus malignant lesions
• Imaging-based risk assessment

Participants gain practical insights into improving diagnostic accuracy.

Emerging Therapeutics in Hepatology

Sessions review new and emerging therapies transforming liver disease management.

Topics include:

• Novel MASH treatments
• GLP-1 receptor agonists
• Fibrosis-targeted therapies
• Hepatology clinical trials
• Personalized treatment strategies
• Future directions in liver disease care

Faculty discuss how emerging therapies are reshaping hepatology practice.

Target Audience

This course is ideal for:

• Hepatologists
• Gastroenterologists
• GI Surgeons
• Internal Medicine Physicians
• Family Medicine Physicians
• Hospitalists
• Nurse Practitioners
• Physician Assistants
• Advanced Practice Providers
• Healthcare Professionals Interested in Liver Disease

   Topics

1. 01 Advances in MASH

2. 02 Updates in ALD (10 Management 10 New Frontiers)

3. 03 Addiction Medicine for the Gastroenterologist Hepatologist

4. 04 Q&A with Panel Session 1

5. 05 Liver Disease in Pregnancy

6. 06 PSC PBC Cases

7. 07 AIH Updates in 2025

8. 08 Panel Q&A Session 2

9. 09 Case Presentation – Hereditary Hemochromatosis

10. 10 Case Presentation – Drug Induced Liver Injury

11. 11 Case Presentation – MASLD

12. 12 Panel Q&A – Coffee, Weight Loss and GLP-1s to Treat MASLD

13. 13 Debate Primary Prophylaxis of Esophageal Varices

14. 14 Management of Ascites; SBP Prophylaxis

15. 15 Patient Cases (PVT – INCPH)

16. 16 Panel Q&A – Ascites, Portal Vein Thrombosis, and Anticoagulation in Cirrhosis

17. 17 Patient Cases (HBV – Treatment, HBVr New Practice Guidelines)

18. 18 Referral for LTE

19. 19 Malnutrition and Frailty in the Cirrhosis Patient

20. 20 Updates in HCC Surveillance

21. 21 Liver Lesion Cases (Benign, LR-3 LR-4, HCC)